Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 352 of the 356 references it cites were found in a registry or an index; none of the 390 sources its claims cite is checked for support yet.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of polycystic ovary syndrome (PCOS). PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence. CONCLUSIONS: We suggest using the Rotterdam criteria for diagnosing PCOS (presence of two of the following criteria: androgen excess, ovulatory dysfunction, or polycystic ovaries). Establishing a diagnosis of PCOS is problematic in adolescents and menopausal women. Hyperandrogenism is central to the presentation in adolescents, whereas there is no consistent phenotype in postmenopausal women. Evaluation of women with PCOS should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease. Hormonal contraceptives are the first-line management for menstrual abnormalities and hirsutism/acne in PCOS. Clomiphene is currently the first-line therapy for infertility; metformin is beneficial for metabolic/glycemic abnormalities and for improving menstrual irregularities, but it has limited or no benefit in treating hirsutism, acne, or infertility. Hormonal contraceptives and metformin are the treatment options in adolescents with PCOS. The role of weight loss in improving PCOS status per se is uncertain, but lifestyle intervention is beneficial in overweight/obese patients for other health benefits. Thiazolidinediones have an unfavorable risk-benefit ratio overall, and statins require further study.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends using the Rotterdam criteria to diagnose PCOS in adults and emphasizes excluding mimics and assessing associated metabolic, cardiovascular, endometrial, mood, and sleep morbidity. It recommends hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism/acne, clomiphene (or comparable estrogen modulators) as first-line therapy for anovulatory infertility, and metformin for T2DM/IGT or as second-line therapy for menstrual irregularity when hormonal contraceptives cannot be used.
Key findings
- PCOS diagnosis in adults should be made if two of three Rotterdam criteria are met—androgen excess, ovulatory dysfunction, or polycystic ovaries—after excluding thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia; in adolescents, diagnosis should require clinical and/or biochemical hyperandrogenism plus persistent oligomenorrhea, because anovulatory symptoms and PCO morphology are not sufficient.
- Women with PCOS are at increased risk for impaired glucose tolerance and type 2 diabetes: the guideline states a 5- to 10-fold increased risk of developing T2DM, with overall glucose intolerance prevalence of 30–35% and T2DM in 3–10%; nonobese women with PCOS had 10–15% IGT and 1–2% T2DM.
- Hirsutism is present in approximately 65–75% of patients with PCOS, and PCOS represents the major cause of hirsutism; in a large study of patients with clinical hyperandrogenism, 72.1% of 950 patients were diagnosed with PCOS.
- Endometrial cancer risk is increased: a 31-year UK follow-up showed a 3.5 increased relative risk, and a meta-analysis reported RR = 2.7 (95% CI, 1.0–7.29), confirmed by a subsequent systematic review with a 3-fold increased risk.
- Depression and sleep-disordered breathing are also increased: one study reported major depression episode/recurrent depression OR 3.8 (95% CI, 1.5–8.7; P = .001) and suicide attempts seven times higher in PCOS cases vs controls; women with PCOS were 30 times more likely to have sleep-disordered breathing and nine times more likely to have daytime sleepiness after controlling for BMI.
Methods
- An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline using the GRADE system to describe recommendation strength and evidence quality.
- Consensus was reached through one group meeting, several conference calls, and e-mail communications; committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts.
- Two systematic reviews were conducted to summarize supporting evidence; recommendations use “we recommend” with number 1 for strong recommendations and “we suggest” with number 2 for weak recommendations, with cross-filled circles indicating evidence quality.
Limitations
- The guideline states that there are no adequately powered, randomized, double-blind, placebo-controlled trials in adolescents with PCOS; no large randomized trials of exercise in PCOS; and no long-term data assessing the effect of hormonal contraceptives on glucose tolerance in nondiabetic and diabetic women with PCOS.
- It states that there are currently no diagnostic criteria for PCOS in perimenopausal and menopausal women, no age-related testosterone cutoffs, and that testosterone assays used to diagnose hyperandrogenemia in women are imprecise.
- It notes that the Rotterdam ultrasound PCO criteria were not validated for adolescents, that there is a lack of well-defined cutoff points for androgen levels during normal pubertal maturation, and that many recommendations are weak because evidence is limited or inconclusive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 201 Not checked · 50 Own results and interpretations
In the paper
“However, hirsutism was a major symptom in about 60% of adolescents in one study (27) and may be suggestive of PCOS in adolescents (28).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.0 Diagnosis of PCOS
What the sources say
- Not checked yetcites [27] Pfeifer SM, Kives S Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am. 2009; 36: 129– 152. 19344852
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“but our systematic review did not confirm this (211).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [211] Domecq JP, Prutsky G, Mullan R, et al Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013–2385. 24092832
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“although there were significant improvements in some metabolic parameters (mainly glycemic effects related to improvements in fasting blood glucose and insulin levels) (249, 250).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found little evidence to support lifestyle change as an infertility treatment”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Our own meta-analysis showed that weight loss had minimal effects on hirsutism and fertility”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
146 more claims
Create a free account to see all 252 claims and to verify the 390 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 34
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on current guidelines, metformin is indicated in PCOS in some scenarios to improve fertility (Teede et al. , 2011; Legro et al. , 2013), for management of menstrual irregularity if women are unable to take OCPs, and in co-existent prediabetes or DM2, where lifestyle modification fails (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the interim there is inadequate evidence on the impact of metformin on glucose tolerance in prediabetes and DM2 specifically in PCOS, but based on data in general populations, current guidelines recommend using metformin in obese women with PCOS who have prediabetes or DM2 (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al. , 2013
Experimental — accuracy not yet measuredIn the citing paper
“It is indicated in combination with COCs, especially for overweight or obese patients, or when COCs are contraindicated [46].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [46]
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“implementation of evidence-based guidelines (4).”
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Self-citationThe diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 1×
“Cushing’s syndrome Many of the signs and symptoms of PCOS can overlap with Cushing’s (ie, striae, obesity, dorsocervical fat (ie, buffalo hump, glucose intolerance); however, Cushing’s is more likely to be present when a large number of signs and symptoms, especially those with high discriminatory index (eg, myopathy,…”
BackgroundThe Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 1×
“Overall, hirsutism is present in approximately 65–75% of patients with PCOS (although lower in Asian populations) (15, 52).”
BackgroundPhysical Fitness and All-Cause Mortality: A Prospective Study of Healthy Men and Women
Blair, S. N. (1989) · JAMA · doi:10.1001/jama.1989.03430170057028 · Cited by 2,658 · cited 1×
“diovascular fitness, as measured by maximal oxygen consumption during exercise, is an independent predictor of cardiovascular mortality (229).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“Similarly, androgen levels decline with age in women with and without PCOS (serum T declines 50% between the ages of 20 and 40 y) (43–45), with reports of improved menstrual frequency in PCOS (46, 47), although there is little evidence to support a decline in serum T associated with the menopause transition per se (43…”
BackgroundSelf-citation
Research works printed but not linked: 1
- [286]Tanner JM Growth and endocrinology of the adolescent. In: Gardner LI, ed. Endocrine and Genetic Diseases of Childhood and Adolescents. 2nd ed Philadelphia, PA: WB Saunders: 1975: 14.
Cited by
Items 101–200 of 1,004
Ollila, M.-M. E., West, S., Keinänen-Kiukaanniemi, S., Jokelainen, J., Auvinen, J., Puukka, K., Ruokonen, A., Järvelin, M.-R., Tapanainen, J. S., Franks, S., et al. (2017) · Human Reproduction · doi:10.1093/humrep/dew329 · Cited by 165
“Despite the aforementioned inconsistent results, consensus statements by the Endocrine Society (Legro et al., 2013), the Androgen Excess and Polycystic Ovary Syndrome Society (AE-PCOS) (Wild et al., 2010) and the Australian PCOS Alliance guidelines (Evidence-based guidelines for the assessment and management of polycy…”
ResultThe Mechanism of Androgen Actions in PCOS Etiology
Rodriguez Paris, V., & Bertoldo, M. J. (2019) · Medical Sciences · doi:10.3390/medsci7090089 · Cited by 133
“In PCOS patients, third generation combined oral contraceptive pills that comprise antiandrogenic compounds, have demonstrated a beneficial effect on the metabolic phenotypes of PCOS, with patients displaying enhanced lipid and adipokine profiles [22].”
BackgroundZhang, N., Liu, X., Zhuang, L., Liu, X., Zhao, H., Shan, Y., Liu, Z., Li, F., Wang, Y., & Fang, J. (2019) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2019.104544 · Cited by 164
Jobira, B., Frank, D. N., Pyle, L., Silveira, L. J., Kelsey, M. M., Garcia-Reyes, Y., Robertson, C. E., Ir, D., Nadeau, K. J., & Cree-Green, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz263 · Cited by 162
Prenatal androgen exposure causes hypertension and gut microbiota dysbiosis
Sherman, S. B., Sarsour, N., Salehi, M., Schroering, A., Mell, B., Joe, B., & Hill, J. W. (2018) · Gut Microbes · doi:10.1080/19490976.2018.1441664 · Cited by 162
Dokras, A., Sarwer, D. B., Allison, K. C., Milman, L., Kris-Etherton, P. M., Kunselman, A. R., Stetter, C. M., Williams, N. I., Gnatuk, C. L., Estes, S. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1896 · Cited by 161
Self-citationJahan, S., Abid, A., Khalid, S., Afsar, T., Ain, Q. U., Shaheen, G., Almajwal, A. M., & Razak, S. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0400-5 · Cited by 160
“Insulin sensitizers like metformin and derivatives of thiazolidinedione are extensively used in controlling PCOS [8].”
BackgroundNutrition in Gynecological Diseases: Current Perspectives
Ciebiera, M., Esfandyari, S., Siblini, H., Prince, L., Elkafas, H., Wojtyła, C., Al-Hendy, A., & Ali, M. (2021) · Nutrients · doi:10.3390/nu13041178 · Cited by 108
“Considering the effect of high insulin levels on the production of testosterone and the high levels of this androgen in PCOS women, improving insulin sensitivity by changing the diet and lifestyle may be regarded as the first-line treatment in this disorder [46,47].”
BackgroundDeswal, R., Yadav, A., & Dang, A. S. (2018) · Systems Biology in Reproductive Medicine · doi:10.1080/19396368.2017.1410591 · Cited by 159
“…case control study measuring levels of SHBG in PCOS women, ii) PCOS was diagnosed either by Rotterdam, or NIH, or AES criteria [Azziz et al. 2009; Legro et al. 2013], iii) studies found an association of SHBG with various endocrine and metabolic abnormalities present in PCOS women, iv) there was…”
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Han, Y., Li, Y., & He, B. (2019) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2019.04.017 · Cited by 159
Trikudanathan, S. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.09.003 · Cited by 159
Wang, R., Kim, B. V., van Wely, M., Johnson, N. P., Costello, M. F., Zhang, H., Ng, E. H. Y., Legro, R. S., Bhattacharya, S., Norman, R. J., et al. (2017) · BMJ · doi:10.1136/bmj.j138 · Cited by 133
Self-citationIs fertility reduced in ovulatory women with polycystic ovary syndrome? An opinion paper
Palomba, S. (2021) · Human Reproduction · doi:10.1093/humrep/deab181 · Cited by 161
Sidra, S., Tariq, M. H., Farrukh, M. J., & Mohsin, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223329 · Cited by 155
“However, the Endocrine Society recommends that PCOS should be diagnosed when adult women present with two of the following features: excess androgen production, anovulation, and pearl-sized cysts in the ovaries [17].”
BackgroundInfluentialThe Role of Zinc in Selected Female Reproductive System Disorders
Nasiadek, M., Stragierowicz, J., Klimczak, M., & Kilanowicz, A. (2020) · Nutrients · doi:10.3390/nu12082464 · Cited by 158
“The pathogenesis of this disease still remains unclear, but PCOS is manifested by: dysregulation in menstrual cycle, hyperandrogenism, insulin resistance and impaired hormonal and lipid balance [44].”
BackgroundGlintborg, D., Hass Rubin, K., Nybo, M., Abrahamsen, B., & Andersen, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1108 · Cited by 154
Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach
Toosy, S., Sodi, R., & Pappachan, J. M. (2018) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-018-0371-5 · Cited by 154
Al Wattar, B. H., Fisher, M., Bevington, L., Talaulikar, V., Davies, M., Conway, G., & Yasmin, E. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab232 · Cited by 123
Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause
Welt, C. K., & Carmina, E. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2375 · Cited by 148
Self-citationCostello, M. F., Misso, M. L., Balen, A., Boyle, J., Devoto, L., Garad, R. M., Hart, R., Johnson, L., Jordan, C., Legro, R. S., et al. (2019) · Human Reproduction Open · doi:10.1093/hropen/hoy021 · Cited by 122
“…either are limited in breadth, do not follow rigorous best practice in development, have not involved consumers or are outdated (Teede et al., 2011; Legro et al., 2013; Conway et al., 2014; Goodman et al., 2015; Balen et al., 2016) resulting in inconsistent guidance for clinicians and women alike.”
BackgroundSelf-citationPolycystic Ovary Syndrome: Update on Diagnosis and Treatment
Setji, T. L., & Brown, A. J. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.04.017 · Cited by 145
Heshmati, J., Moini, A., Sepidarkish, M., Morvaridzadeh, M., Salehi, M., Palmowski, A., Mojtahedi, M. F., & Shidfar, F. (2021) · Phytomedicine · doi:10.1016/j.phymed.2020.153395 · Cited by 142
Recent advances in the understanding and management of polycystic ovary syndrome
Rocha, A. L., Oliveira, F. R., Azevedo, R. C., Silva, V. A., Peres, T. M., Candido, A. L., Gomes, K. B., & Reis, F. M. (2019) · F1000Research · doi:10.12688/f1000research.15318.1 · Cited by 142
Criteria, phenotypes and prevalence of polycystic ovary syndrome
Belenkaia, L. V., Лазарева, Л. М., Walker, W., Lizneva, D., & Сутурина, Л. В. (2019) · Minerva Obstetrics and Gynecology · doi:10.23736/s0026-4784.19.04404-6 · Cited by 145
Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
Srivastava, G., Fox, C. K., Kelly, A. S., Jastreboff, A. M., Browne, A. F., Browne, N. T., Pratt, J. S. A., Bolling, C., Michalsky, M. P., Cook, S., et al. (2019) · Obesity · doi:10.1002/oby.22385 · Cited by 130
“Metformin is extensively utilized for polycystic ovarian syndrome treatment with or without obesity diagnosis in children and adolescents, with improvement seen on lipid profile, hirsutism, and weight loss (82-84).”
BackgroundAn update of genetic basis of PCOS pathogenesis
Crespo, R. P., Bachega, T. A. S. S., Mendonça, B. B., & Gomes, L. G. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000049 · Cited by 138
“More recently, a Consensus by NIH tried to unify the recommendations, suggesting the use of the Rotterdam Consensus for PCOS diagnosis in order to include the four phenotypes possibilities, and thus expanding the population with PCOS to its largest number (6).”
MethodGeorge, J. T., Kakkar, R., Marshall, J., Scott, M. L., Finkelman, R. D., Ho, T. W., Veldhuis, J., Skorupskaite, K., Anderson, R. A., McIntosh, S., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1202 · Cited by 131
“Several exploratory endpoints were investigated: (1) the change from baseline in LH AUC on day 28 relative to placebo; (2) changes from baseline in FSH, estradiol, progesterone, prolactin, thyroid-stimulating hormone, and insulin-like growth factor-1 on days 7 and 28; (3) glycated hemoglobin concentration on day 28; (…”
BackgroundMethodJamilian, M., Foroozanfard, F., Rahmani, E., Talebi, M., Bahmani, F., & Asemi, Z. (2017) · Nutrients · doi:10.3390/nu9121280 · Cited by 115
“All patients were taking the metformin tablet at the initial dose of 500 mg, which was enhanced in a stepwise manner during the first 3 weeks to incorporate the side effects until the patients were taking a total of 1500 mg/day [17].”
MethodPediatric obesity: Current concepts
Greydanus, D. E., Agana, M. G., Kamboj, M. K., Shebrain, S., Soares, N. S., Eke, R., & Patel, D. R. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2017.12.001 · Cited by 129
Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review
Livadas, S., Anagnostis, P. G., Bosdou, J. Κ., Bantouna, D., & Paparodis, R. D. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i1.5 · Cited by 131
Islam, H., Masud, J., Islam, Y. N., & Haque, F. K. M. (2022) · Women s Health · doi:10.1177/17455057221117966 · Cited by 133
Lin, A. W., Kazemi, M., Jarrett, B. Y., Vanden Brink, H., Hoeger, K. M., Spandorfer, S. D., & Lujan, M. E. (2019) · Nutrients · doi:10.3390/nu11112711 · Cited by 110
“Although preliminary evidence suggests that women with PCOS are more susceptible to weight gain [6], controversy exists on whether dietary and physical activity behaviors contribute to the development of PCOS [4,6].”
BackgroundSelf-citationIzadi, A., Ebrahimi, S., Shirzai, S., Taghizadeh, S., Parizad, M., Farzadi, L., & Pourghassem Gargari, B. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01221 · Cited by 95
Guan, Y., Wang, D., Bu, H., Zhao, T., & Wang, H. (2020) · International Journal of Endocrinology · doi:10.1155/2020/5150684 · Cited by 106
“Polycystic ovary syndrome (PCOS) is a common gynaecological endocrine disease in women of childbearing age [1].”
BackgroundHypertension in Reproductive-Aged Women With Polycystic Ovary Syndrome and Association With Obesity
Joham, A. E., Boyle, J. A., Zoungas, S., & Teede, H. J. (2015) · American Journal of Hypertension · doi:10.1093/ajh/hpu251 · Cited by 114
Zhao, X., Jiang, Y., Xi, H., Chen, L., & Feng, X. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1081-2036 · Cited by 124
“…and other complications of PCOS should be included in the diagnosis and treatment of PCOS has been emphasized by several reproductive endocrine institutions, including the National Institutes of Health (NIH), the American Endocrine Society, the European Endocrine Society and others [6,7].”
Handelsman, D. J., Sikaris, K., & Ly, L. P. (2016) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563215610589 · Cited by 122
“component of polycystic ovary syndrome, the most frequent endocrinopathy of young females.(3,4) Yet, despite the significance of circulating testosterone throughout the lifespan, there is no report of the age-specific profile of circulating testosterone in males and females from birth to advanced old age.”
BackgroundJaved, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019) · Clinical Endocrinology · doi:10.1111/cen.13968 · Cited by 121
Metabolism and Ovarian Function in PCOS Women: A Therapeutic Approach with Inositols
Laganà, A. S., Rossetti, P., Buscema, M., La Vignera, S., Condorelli, R. A., Gullo, G., Granese, R., & Triolo, O. (2016) · International Journal of Endocrinology · doi:10.1155/2016/6306410 · Cited by 109
“Metformin is recommended both in patients with metabolic abnormalities (such as IGT, IFG, and type 2 diabetes) and inwomenwho desire pregnancy, as an adjuvant therapy for infertility and to decrease the risk of ovarian hyperstimulation syndrome [36].”
BackgroundHosain, A. K. M. S., Mehedi, M. H. K., & Kabir, I. E. (2022) · International Conference on Engineering and Emerging Technologies (ICEET) · doi:10.1109/iceet56468.2022.10007353 · Cited by 124
“The most prevalent PCOS categorization is the Rotterdam definition, which is supported by the majority of scientific associations and health agencies at present [8].”
BackgroundMANAGEMENT OF ENDOCRINE DISEASE: Hyperandrogenism after menopause
Markopoulos, M. C., Kassi, E., Alexandraki, K. I., Mastorakos, G., & Kaltsas, G. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0468 · Cited by 105
Clark, R. V., Wald, J. A., Swerdloff, R. S., Wang, C., Wu, F. C. W., Bowers, L. D., & Matsumoto, A. M. (2019) · Clinical Endocrinology · doi:10.1111/cen.13840 · Cited by 103
Assessment of free testosterone concentration
Keevil, B. G., & Adaway, J. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.008 · Cited by 111
Shared decision making in endocrinology: Present and future directions
Rodriguez-Gutierrez, R., Gionfriddo, M. R., Ospina, N. S., Maraka, S., Tamhane, S., Montori, V. M., & Brito, J. P. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00468-4 · Cited by 117
Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome
Kelley, C. E. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14172 · Cited by 100
Zhang, L., Wang, F., Li, D., Yan, Y.-F., & Wang, H. (2021) · Bioengineered · doi:10.1080/21655979.2021.1956403 · Cited by 117
“The strategies for treating PCOS mainly focus on treating menstrual irregularities, hirsutism, and androgen resistance, with laparoscopic ovarian drilling being the main technique focused on [4].”
BackgroundAbdolahian, S., Tehrani, F. R., Amiri, M., Ghodsi, D., Yarandi, R. B., Jafari, M., Majd, H. A., & Nahidi, F. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00552-1 · Cited by 84
“Similar to our findings, two other studies showed that weight reduction, through increasing physical exercise alone, can be effective in regulating menstrual cycles [11, 49].”
ResultHelvaci, N., Karabulut, E., Demir, A. U., & Yildiz, B. O. (2017) · Endocrine Connections · doi:10.1530/ec-17-0129 · Cited by 115
Burden of polycystic ovary syndrome in the Middle East and North Africa region, 1990–2019
Asghari, K. M., Nejadghaderi, S. A., Alizadeh, M., Sanaie, S., Sullman, M. J. M., Kolahi, A., Avery, J., & Safiri, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-11006-0 · Cited by 120
Menstrual Cycle Effects on Sleep
Baker, F. C., & Lee, K. A. (2022) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2022.02.004 · Cited by 115
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0252 · Cited by 113
Self-citationAdrenal Androgens and Androgen Precursors-Definition, Synthesis, Regulation and Physiologic Actions
Turcu, A., Smith, J. M., Auchus, R., & Rainey, W. E. (2014) · Comprehensive physiology · doi:10.1002/cphy.c140006 · Cited by 113
“In addition, there was a brief period of support for AASH being the proximal 18-amino acid hinge region (amino acids 79-96) of POMC, but the initial studies were not confirmed by additional in vitro studies (107,127,132).”
Women's experiences of polycystic ovary syndrome diagnosis
Gibson-Helm, M. E., Lucas, I. M., Boyle, J. A., & Teede, H. J. (2014) · Family Practice · doi:10.1093/fampra/cmu028 · Cited by 112
Acupuncture for polycystic ovarian syndrome
Lim, C. E. D., Ng, R. W. C., Cheng, N. C. L., Zhang, G. S., & Chen, H. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007689.pub4 · Cited by 112
Polycystic Ovary Syndrome Is Associated With Adverse Mental Health and Neurodevelopmental Outcomes
Berni, T. R., Morgan, C. L., Berni, E. R., & Rees, D. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02667 · Cited by 111
Lipodystrophy: A paradigm for understanding the consequences of "overloading" adipose tissue
Lim, K., Haider, A., Adams, C., Sleigh, A., & Savage, D. B. (2020) · Physiological Reviews · doi:10.1152/physrev.00032.2020 · Cited by 111
Lerchbaum, E., Schwetz, V., Rabe, T., Giuliani, A., & Obermayer-Pietsch, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108263 · Cited by 110
“The current clinical practice guidelines from the Endocrine Society recommend the use of elevated total, bioavailable, or free serum testosterone level for PCOS diagnosis [11].”
MethodHaidari, F., Banaei-Jahromi, N., Zakerkish, M., & Ahmadi, K. (2020) · Nutrition Journal · doi:10.1186/s12937-020-0524-5 · Cited by 91
“Yet, attention to medicinal herbs has recently expanded as an alternative treatment or diseases control [13].”
BackgroundYuan, D., Luo, J., Sun, Y., Hao, L., Zheng, J., & Yang, Z. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110030 · Cited by 110
The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes
Çakıroğlu, Y., Vural, F., & Vural, B. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0446-4 · Cited by 109
Trummer, C., Schwetz, V., Kollmann, M., Wölfler, M., Münzker, J., Pieber, T. R., Pilz, S., Heijboer, A. C., Obermayer-Pietsch, B., & Lerchbaum, E. (2019) · European Journal of Nutrition · doi:10.1007/s00394-018-1760-8 · Cited by 87
Targher, G., Rossini, M., & Lonardo, A. (2015) · Endocrine · doi:10.1007/s12020-015-0640-8 · Cited by 110
Polycystic ovary syndrome in adolescents
Rothenberg, S. S., Beverley, R. M., Barnard, E., Baradaran-Shoraka, M., & Sanfilippo, J. S. (2017) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2017.08.008 · Cited by 107
Androgens and ovarian function: translation from basic discovery research to clinical impact
Walters, K. A., Rodriguez Paris, V, Aflatounian, A., & Handelsman, D. J. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0096 · Cited by 104
Hormonal Contraceptives and Mood: Review of the Literature and Implications for Future Research
Robakis, T., Williams, K. E., Nutkiewicz, L., & Rasgon, N. L. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1034-z · Cited by 103
Jensterle, M., Salamun, V., Kocjan, T., Vrtacnik Bokal, E., & Janez, A. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0161-3 · Cited by 103
“Although metformin is still widely used in the management of PCOS due to its observed curative and potentially preventive clinical benefits, including body weight reduction and improvement of fat distribution, recent guidelines developed by the Endocrine Society recommended its use only in women with PCOS who are alre…”
BackgroundApproach to the Patient: Contraception in Women With Polycystic Ovary Syndrome
Yildiz, B. O. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3196 · Cited by 90
“They also emphasize that there is no definitive evidence for any difference in efficacy of various OCs (5, 17).”
BackgroundCarmina, E., Dréno, B., LUCKY, W., Agak, G. W., Dokras, A., Kim, J., Løbo, R. A., Tehrani, F. R., & Dumesic, D. A. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac003 · Cited by 105
Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome
Hu, L., Ma, L., Xia, X., Ying, T., Zhou, M., Zou, S., Yu, H., & Yin, J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac294 · Cited by 104
Neuroendocrine Determinants of Polycystic Ovary Syndrome
Szeliga, A., Rudnicka, E., Maciejewska-Jeske, M., Kucharski, M., Kostrzak, A., Hajbos, M., Niwczyk, O., Smolarczyk, R., & Męczekalski, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19053089 · Cited by 101
“GLP-1 RA treatment increases accessible plasma GLP1 to supraphysiologic levels, increasing glucose-dependent insulin secretion, decreasing glucagon production, slowing gastric emptying, and increasing satiety [67].”
BackgroundBarrea, L., Muscogiuri, G., Pugliese, G., de Alteriis, G., Colao, A., & Savastano, S. (2021) · Nutrients · doi:10.3390/nu13113925 · Cited by 99
“â Oligomenorrhea, biochemical hyperandrogenemia, and/or hyperandrogenism due to secondary aetiologies including endocrine disorders as per the Endocrine Society Clinical Practice Guidelines and previous publications [24]; â Pre-existing systemic or psychiatric disease; â Use of drugs that influence lipid or carbohydra…”
BackgroundMenstrual suppression: current perspectives
Hillard, P. J. A. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s46680 · Cited by 99
Practical Approach to Hyperandrogenism in Women
Sharma, A. R., & Welt, C. K. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.008 · Cited by 101
Self-citationEndocrine causes of nonalcoholic fatty liver disease
Marino, L., & Jornayvaz, F. R. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11053 · Cited by 101
Sun, Y., Zhang, J., Xu, Y., Cao, Z.-Y., Wang, Y.-Z., Hao, G., & Gao, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.592495 · Cited by 98
Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies
Kamboj, M. K., & Bonny, A. E. (2017) · Translational Pediatrics · doi:10.21037/tp.2017.09.11 · Cited by 101
“Recent l i tera ture has recognized these deficiencies and evidence based expert recommendations have become more available (4-6).”
BackgroundAnxiety and Depression in Women with Polycystic Ovary Syndrome
Dybciak, P., Humeniuk, E., Raczkiewicz, D., Krakowiak, J., Wdowiak, A., & Bojar, I. (2022) · Medicina · doi:10.3390/medicina58070942 · Cited by 101
Effect of COVID-19 vaccination on the timing and flow of menstrual periods in two cohorts
Alvergne, A., Woon, E. V., & Male, V. H. (2022) · Frontiers in Reproductive Health · doi:10.3389/frph.2022.952976 · Cited by 98
Gadalla, M. A., Huang, S., Wang, R., Norman, R. J., Abdullah, S. A., Saman, A. M. E., Ismail, A., van Wely, M., & Mol, B. W. (2017) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.18933 · Cited by 99
The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum
Rosenfield, R. L. (2015) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2014.07.016 · Cited by 76
Current aspects of polycystic ovary syndrome: A literature review
ANDRADE, V. H. L. D., da Mata, A. M. O. F., Borges, R. S., Costa-Silva, D. R., Martins, L. M., Ferreira, P. M. P., Nunes, L. C. C., & da Silva, B. B. (2016) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.62.09.867 · Cited by 95
Papadakis, G. E., Kandaraki, E., Tseniklidi, E., Papalou, O., & Diamanti‐Kandarakis, E. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00388 · Cited by 95
Dobbie, L. J., Pittam, B., Zhao, S. S., Alam, U., Hydes, T., Barber, T. M., & Cuthbertson, D. J. (2023) · Human Reproduction · doi:10.1093/humrep/dead053 · Cited by 95
“…(Diamanti-Kandarakis et al. , 1999; Asuncio´n et al. , 2000; Azziz et al. , 2004b), characterized by clinical and/or bio-chemical androgen excess, menstrual abnormalities, and sub-/infertility (Hull, 1987; Balen et al. , 1995b; Boomsma et al. , 2006; Kjerulff et al. , 2011; Legro et al. , 2013).”
Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome
Sam, S., & Ehrmann, D. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4306-3 · Cited by 93
Self-citationCarmina, E., & Løbo, R. A. (2022) · Diagnostics · doi:10.3390/diagnostics12102313 · Cited by 94
Sathyapalan, T., David, R. M., Gooderham, N. J., & Atkin, S. L. (2015) · Scientific Reports · doi:10.1038/srep16890 · Cited by 94
Long term complications of polycystic ovary syndrome (PCOS)
Peigné, M., & Dewailly, D. (2014) · Annales d Endocrinologie · doi:10.1016/j.ando.2014.07.111 · Cited by 92
Metformin or oral contraceptives for adolescents with polycystic ovarian syndrome: a meta-analysis
Al Khalifah, R. A., Florez, I. D., Dennis, B., Thabane, L., & Bassilious, E. (2016) · PEDIATRICS · doi:10.1542/peds.2015-4089 · Cited by 91
Barrera, F. J., Brown, E. D. L., Rojo, A., Obeso, J., Plata, H., Lincango, E. P., Terry, N., Rodríguez-Gutiérrez, R., Hall, J. E., & Shekhar, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1106625 · Cited by 91
Abasian, Z., Rostamzadeh, A., Mohammadi, M., Hosseini, M., & Rafieian‐Kopaei, M. (2018) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2018.04.005 · Cited by 91
The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients
Chang, C. L., Huang, S. Y., Hsu, Y. C., Chin, T. H., & Soong, Y. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-42061-9 · Cited by 92
Application of Stem Cell Therapy for Infertility
Saha, S., Roy, P., Corbitt, C., & Kakar, S. S. (2021) · Cells · doi:10.3390/cells10071613 · Cited by 91
“Patients with PCOS commonly present with irregular menstruation, obesity, abnormal hair growth on the body and infertility/subfertility [158].”
BackgroundAlmhmoud, H., Alatassi, L., Baddoura, M., Sandouk, J., Alkayali, M. Z., Najjar, H., & Zaino, B. (2024) · Medicine · doi:10.1097/md.0000000000038647 · Cited by 91
“[24] The Evidence-Based International Guidelines endorsed the Rotterdam criteria, which assembled healthcare providers to discuss diagnostic criteria and provide beneficial treatment choices.”
MethodLiu, Q., Liu, H., Bai, H., Huang, W., Zhang, R., Tan, J., Guan, L., & Fan, P. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0999-5 · Cited by 90
The last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment
Ghafari, A., Maftoohi, M., Samarin, M. E., Barani, S., Banimohammad, M., & Samie, R. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100228 · Cited by 97
Kazemi, M., Kim, J. Y., Wan, C., Xiong, J. D., Michalak, J., Xavier, I. B., Ganga, K., Tay, C. T., Grieger, J. A., Parry, S. A., et al. (2022) · Human Reproduction Update · doi:10.1093/humupd/dmac023 · Cited by 89
Criteria for Diagnosis of Polycystic Ovary Syndrome during Adolescence: Literature Review
Peña, A. S., Ethel Codner, D., & Witchel, S. F. (2022) · Diagnostics · doi:10.3390/diagnostics12081931 · Cited by 90
Orio, F., Muscogiuri, G., Giallauria, F., Savastano, S., Bottiglieri, P., Tafuri, D., Predotti, P., Colarieti, G., Colao, A., & Palomba, S. (2016) · Clinical Endocrinology · doi:10.1111/cen.13112 · Cited by 74
Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women
Elhassan, Y. S., Idkowiak, J., Smith, K., Asia, M., Gleeson, H., Webster, R., Arlt, W., & O’Reilly, M. W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02426 · Cited by 80
Genetics and Epigenetics of Infertility and Treatments on Outcomes
Pisarska, M. D., Chan, J. L., Lawrenson, K., Gonzalez, T. L., & Wang, E. T. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01869 · Cited by 90
Metadata
- Authors
- Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K.
- Affiliations
- Pennsylvania State University (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12
- Volume
- 98
- Issue
- 12
- Pages
- 4565-4592
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5399492
- OpenAlex
- W2120973019
- Cited by
- 1,919
- References
- 356
- Citations by year
- 2026: 104 · 2025: 135 · 2024: 149 · 2023: 181 · 2022: 207 · 2021: 197 · 2020: 149 · 2019: 160 · 2018: 145 · 2017: 129 · 2016: 131 · 2015: 124 · 2014: 95 · 2013: 6
- FWCI
- 143.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institute of Diabetes and Digestive and Kidney Diseases (P60DK020595, P30DK020595)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065029)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, PCOS diagnosis, Rotterdam criteria, hyperandrogenism, ovulatory dysfunction, PCOS treatment, hormonal contraception, clomiphene citrate, metformin, insulin resistance, menstrual irregularity, hirsutism, acne, infertility, adolescents, menopausal women, weight loss, lifestyle intervention, thiazolidinediones, statins, cardiovascular risk
- MeSH terms
- Adolescent, Adult, Age Factors, Female, Humans, Middle Aged, Polycystic Ovary Syndrome, Societies, Scientific, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.